Expert video report on pancreatobiliary cancers

ASCO 2019

Speaker: Angela Lamarca

A. Lamarca reports on study results presented on pancreatobiliary cancers at ASCO 2019. She explains the importance of testing for BRCA gene mutations in pancreatic cancer patients and discusses chemotherapy versus active symptoms control in second-line management of advanced/metastatic biliary cancer.

Abstract discussed:

  • LBA4 / Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.
  • Abstract 4003 / ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.